St Paul, MN March 4, 2008 – MD Biosciences, a global biotechnology company focused in inflammations research, announces the recent launch of its new line of Mouse anti-Collagen Type II (anti-mouse CII) ELISAs. The new Mouse anti-collagen CII ELISAs allow you to measure antibodies generated against the species of collagen used in the induction of arthritis in mice (bovine, human, mouse, rat, chicken, porcine). IgG and two subclasses (IgG2a and IgG2b) are now available as ready-to-use ELISAs that provide fast, accurate and reliable results.
The Collagen-induced arthritis (CIA) model is one of the most widely used models for the study of RA. Collagen type II (CII) in adjuvant is used to induce arthritis by triggering autoreactive B cells, which play an important role in the development of arthritis. This B cell response to CII is strictly T cell dependent, where the B cells predominantly switch isotype to IgG.
The anti-Type II Collagen ELISAs offer many improvements over other commercially available anti-Collagen Type II ELISAs. The kits come ready to use eliminating any plate coating or blocking as well as eliminates lengthy sample incubations. The assays can be completed in under 3 hours using only 100 uL of sample. Performance characteristics such as precision CVs less than 10%, recovery and linearity averaging at 82% and 102% respectively, and cross-reactivity with other collagen types of less than 0.004% provide reliable, accurate and sensitive assays for the detection mouse Collagen Type II antibodies.
The addition of these assays enhances the arthritis products and services currently offered by MD Biosciences. Research products include assays for measuring type II collagen and antibodies, assay for staining type II collagen, induction reagents such as collagen, adjuvant and ArthritoMabÒ antibody cocktail. Pre-clinical services include collagen-induced arthritis (CIA), Antibody induced arthritis (CAIA), Adjuvant Induced Arthritis as well as in vitro disease models providing the researcher a well-rounded approach for using MD Biosciences products in-house as well as outsourcing other areas of their drug discovery platform.
About MD Biosciences
MD Biosciences provides products and pre-clinical services for companies engaged in inflammations and neurology research. The company is headquartered in Switzerland under Morwell Diagnostics and has specialized laboratories located in Minnesota, Glasgow, and Israel. A panel of scientific experts provides companies’ in-depth expertise and technologies to tackle problems and provide flexible drug discovery solutions, enabling smarter results faster.
###
The information in this press release should be considered accurate only as of the date of the release. MD Biosciences has no intention of updating and specifically disclaims any duty to update the information in these press releases.
